17 results about "Bone marrow fibrosis" patented technology

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The application includes a description of anti-hemojuvelin antibodies and methods for their use in the treatment of myelofibrosis and / or myelofibrosis-related conditions.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The present invention belongs to the field of medicinal chemistry, relates to use of a pyrrolopyrimidine compound in the treatment of medium-risk or high-risk myelofibrosis, and specifically relates to use of a compound of formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same in the treatment of medium-risk or high-risk myelofibrosis. The compound of formula I, the stereoisomer thereof, the pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof has a good therapeutic effect.

For example, to provide a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors such as imetelstat. [Solution] This disclosure provides a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors, such as imetelstat, by testing for high molecular weight risk (HMR) based on the absence of mutations in each of JAK2, CALR, and MPL, and / or the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1 / 2. These patients may have myelofibrosis. This disclosure also provides a method for treating myelofibrosis, the method of which includes identifying such patients.

This invention provides a method for treating anemia in subjects with myelofibrosis. [Solution] A method is provided for treating anemia in a subject with myelofibrosis, comprising administering an effective amount of a hemoduvelin-induced BMP signaling antagonist, a hepcidin antagonist, to the subject.

This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

The present invention provides pharmaceutical compositions and methods of use of bisbenzylisoquinoline, e.g., 6,6',7,12-tetramethoxy-2,2'-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms of the compound, e.g., in crystalline, salt, or salt form, in combination with pharmaceutically acceptable acids or other agents, for the treatment of acute, chronic, and preleukemic conditions, as well as lymphoma and solid tumors. These include, but are not limited to, preneoplastic and neoplastic diseases and solid tumors, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), myelofibrosis (MF), and polycythemia vera (PV).

Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109 / L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.

This article provides the medical use of CXCR4-enriched regulatory T cells in combination with ruxolitinib for the treatment of myelofibrosis or to improve symptoms of myelofibrosis in subjects who have poor response to ruxolitinib monotherapy.

The present disclosure is directed to the use of a menin inhibitor, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more therapeutically active agent, for treating, preventing, reducing the progression rate, and / or reducing the severity of myeloproliferative neoplasms (e.g., myelofibrosis, essential thrombocythemia, triple negative MPN, and polycythemia vera), and pharmaceutical compositions containing the same for treating, preventing, reducing the progression rate, and / or reducing the severity of myeloproliferative neoplasms (e.g., myelofibrosis, essential thrombocythemia, triple negative MPN, and polycythemia vera).

Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109 / L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.